Stockscreener 앱 받기
23.86
1.69%
-0.41
전일 마감가:
$24.27
열려 있는:
$24.16
하루 거래량:
533.77K
Relative Volume:
0.63
시가총액:
$1.32B
수익:
$2.50M
순이익/손실:
$-131.12M
주가수익비율:
-8.3922
EPS:
-2.8431
순현금흐름:
$-112.73M
1주 성능:
-0.29%
1개월 성능:
-6.65%
6개월 성능:
-40.87%
1년 성능:
+79.26%
1일 변동 폭
$23.50
$24.37
1주일 범위
$22.71
$25.08
52주 변동 폭
$9.83
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
23.86 | 1.34B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-10 | 개시 | Mizuho | Outperform |
| 2025-12-04 | 개시 | Wells Fargo | Overweight |
| 2025-11-14 | 개시 | Raymond James | Outperform |
| 2025-09-02 | 개시 | BTIG Research | Buy |
| 2025-07-23 | 개시 | H.C. Wainwright | Buy |
| 2025-07-08 | 개시 | Wedbush | Outperform |
모두보기
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk - Yahoo Finance
MAZE Q1 2026 Earnings: Narrower Loss Surprises Analysts Amid Pipeline ProgressEarnings Acceleration Picks - The League of Women Voters of Texas
Maze Therapeutics (MAZE) price target increased by 11.37% to 44.12 - MSN
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor - TipRanks
[Form 4] Maze Therapeutics, Inc. Insider Trading Activity - Stock Titan
Maze Therapeutics (MAZE) director receives grant of 18,000 stock options exercisable at $23.58 - Stock Titan
Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options - Stock Titan
Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58 - Stock Titan
18,000 Maze Therapeutics (MAZE) options granted to director Andrews - Stock Titan
Maze Therapeutics (MAZE) shareholders elect directors and ratify Ernst & Young - Stock Titan
MAZE: Lead assets show strong efficacy and safety, with pivotal trials and key data readouts set for 2026–2027 - TradingView
MAZE: Directors and auditor ratified by majority vote; no shareholder questions submitted - TradingView
MAZE: Both director nominees and the auditor appointment were approved by majority vote - TradingView
MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockBasic EPS Analysis - newsline.com
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now - Insider Monkey
Maze Therapeutics CEO Sells Shares Worth Around 847000 Dollars - HarianBasis.co
8 Oversold Stocks to Buy Right Now - insidermonkey.com
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? - Yahoo Finance
Maze Therapeutics president sells $381k in common stock By Investing.com - Investing.com Australia
Maze Therapeutics president sells $381k in common stock - Investing.com
Maze Therapeutics (MAZE) CEO’s family trusts sell 6,643 shares - Stock Titan
Maze Therapeutics (MAZE) CMO sells 14,853 shares after option exercise - Stock Titan
Maze Therapeutics to Participate in Two Upcoming Investor Conferences - 富途牛牛
Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Why Is Maze Therapeutics, Inc. (MAZE) Stock Down Today? - Meyka
Coloma trusts sell MAZE shares (MAZE) under Rule 144 notice - Stock Titan
Maze Therapeutics (MAZE) Edges Higher, Consolidating Between Support and ResistanceEarnings Miss Risk - The Legal Advocate
Maze Therapeutics Inc. (MAZE) Edges Higher, Tests Key Resistance ZoneFibonacci Retracement - newsline.com
Maze Therapeutics (MAZE) Edges Higher: Biotech Stock Tests Key Technical LevelsHagopian Line - The Legal Advocate
Maze Therapeutics (MAZE) Rises Modestly as Shares Consolidate Near Key ResistanceATR Trailing Stop - newsline.com
Maze Therapeutics to Present at William Blair and Goldman Sachs Healthcare Conferences in June 2024 - geneonline.com
Watch Maze Therapeutics CEO at Jefferies and Goldman health conferences in June - Stock Titan
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Cuts Target Price to $53 - Moomoo
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information - Minichart
Maze Therapeutics Analyst Ratings and Price Targets | NASDAQ:MAZE - Benzinga
Maze Therapeutics CFO Expands Role Amid Finance Leadership Change - TipRanks
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Protara Therapeutics (TARA) - The Globe and Mail
H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110 - Moomoo
100% Of This Maze Therapeutics Insider's Holdings Were Sold - 富途牛牛
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock By Investing.com - Investing.com Australia
Maze Therapeutics Insider Sold Shares Worth $393,354, According to a Recent SEC Filing - Moomoo
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock - Investing.com
CEO Coloma trusts trim 1,938 Maze Therapeutics (MAZE) shares under 10b5-1 plan - Stock Titan
Maze Therapeutics (MAZE) CMO sells 15,000 shares, exercises options - Stock Titan
Maze Therapeutics, Inc. (MAZE) reports Q1 loss, beats revenue estimates - MSN
HighVista Strategies Sells Maze Therapeutics Shares in Q1 2026News and Statistics - IndexBox
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge - Intellectia AI
JP Morgan Maintains Maze Therapeutics (MAZE) Overweight Recommendation - MSN
Maze Therapeutics Inc (MAZE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Maze Therapeutics Inc 주식 (MAZE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Jun 01 '26 |
Option Exercise |
10.42 |
14,853 |
154,768 |
14,853 |
| Bernstein Harold | President, R&D & CMO |
Jun 01 '26 |
Sale |
25.66 |
14,853 |
381,112 |
0 |
| Dandekar Atul | CSBO |
May 29 '26 |
Option Exercise |
10.42 |
7,500 |
78,150 |
32,308 |
| Dandekar Atul | CSBO |
May 29 '26 |
Sale |
26.34 |
7,500 |
197,554 |
24,808 |
1.27%
1.43%
자본화:
|
볼륨(24시간):